Between Sept 2 , 2011 , and July 11 , 2012 , 124 patients were randomly assigned , of whom five had a endoscopic subscore of 0 or 1 and were excluded from the mITT population , leaving 39 patients in the etrolizumab 100 mg group , 39 in the etrolizumab 300 mg plus LD group , and 41 in the placebo group for the primary analyses .